Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

541 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
Barthelmes D, Campain A, Nguyen P, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, Guymer R, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness! Project Investigators. Barthelmes D, et al. Among authors: simpson jm. Br J Ophthalmol. 2016 Dec;100(12):1640-1645. doi: 10.1136/bjophthalmol-2015-308090. Epub 2016 Mar 18. Br J Ophthalmol. 2016. PMID: 26994110 Free PMC article.
Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab.
Gillies MC, Campain A, Walton R, Simpson JM, Arnold JJ, Guymer RH, McAllister IL, Hunyor AP, Essex RW, Morlet N, Barthelmes D; Fight Retinal Blindness Study Group. Gillies MC, et al. Among authors: simpson jm. Ophthalmology. 2015 Mar;122(3):589-594.e1. doi: 10.1016/j.ophtha.2014.10.001. Epub 2014 Nov 6. Ophthalmology. 2015. PMID: 25458197
Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data.
Barthelmes D, Walton R, Campain AE, Simpson JM, Arnold JJ, McAllister IL, Guymer RH, Hunyor AP, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness! Project Investigators. Barthelmes D, et al. Among authors: simpson jm. Br J Ophthalmol. 2015 Mar;99(3):359-64. doi: 10.1136/bjophthalmol-2014-305514. Epub 2014 Sep 23. Br J Ophthalmol. 2015. PMID: 25249615
541 results